Capnia, Inc. (CAPN): Ernest Mario , director 10% owner of Capnia, Inc. purchased 50,000 shares on Jun 8, 2016. The Insider buying transaction was reported by the company on Jun 9, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.24 per share for a total value of $62,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 25, 2016, Steinar J Engelsen (director) purchased 58,200 shares at $1.31 per share price.On May 23, 2016, Ernest Mario (director) purchased 48,806 shares at $1.19 per share price.Also, On May 16, 2016, Bhatnagar Anish (CEO) purchased 5,000 shares at $1.15 per share price.On May 16, 2016, David D O’toole (officer ) purchased 5,000 shares at $1.15 per share price.
Capnia Inc: On Thursday, Jun 9, 2016 heightened volatility was witnessed in Capnia Inc which led to swings in the share price. The shares opened for trading at $1.21 and hit $1.24 on the upside , eventually ending the session at $1.22, with a gain of 1.67% or 0.02 points. The heightened volatility saw the trading volume jump to 1,31,525 shares. The 52-week high of the share price is $4.15 and the company has a market cap of $19 M . The 52-week low of the share price is at $0.843.
Capnia Inc. develops medical diagnostics and therapeutics based on its technology for precision metering of gas flow. The Company’s diagnostic product CoSense aids in the diagnosis of hemolysis in neonates. The Company is applying its research and development efforts to additional diagnostic products based on its Sensalyze Technology Platform a portfolio of methods and devices which enables CoSense and can be applied to detect a variety of analytes in exhaled breath. The Company’s therapeutic technology involves the use of metered nasal carbon dioxide (CO2) for the potential treatment of various diseases. Serenz is the Company’s allergy therapeutic product candidate. It also launched new initiatives for the development of this technology for the treatment of trigeminally mediated pain disorders such as cluster headache and trigeminal neuralgia.